EA201201277A1 - Кристаллические соли эффективного ингибитора вируса гепатита с - Google Patents

Кристаллические соли эффективного ингибитора вируса гепатита с

Info

Publication number
EA201201277A1
EA201201277A1 EA201201277A EA201201277A EA201201277A1 EA 201201277 A1 EA201201277 A1 EA 201201277A1 EA 201201277 A EA201201277 A EA 201201277A EA 201201277 A EA201201277 A EA 201201277A EA 201201277 A1 EA201201277 A1 EA 201201277A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis virus
virus inhibitor
crystal salts
effective hepatitis
effective
Prior art date
Application number
EA201201277A
Other languages
English (en)
Other versions
EA021805B1 (ru
Inventor
Биншиу Ян
Ка Ип
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43778392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201277(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201201277A1 publication Critical patent/EA201201277A1/ru
Publication of EA021805B1 publication Critical patent/EA021805B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к новым солевым формам соединения (1) трис-(гидроксиметил)аминометана, холина, N-метил-D-глюкамина и к способам их получения, а также к их применению для лечения инфекционного заболевания, вызванного вирусом гепатита С (ВГС)
EA201201277A 2010-03-11 2011-03-10 Кристаллические соли эффективного ингибитора вируса гепатита с EA021805B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31279110P 2010-03-11 2010-03-11
PCT/US2011/027807 WO2011112761A1 (en) 2010-03-11 2011-03-10 Crystalline salts of a potent hcv inhibitor

Publications (2)

Publication Number Publication Date
EA201201277A1 true EA201201277A1 (ru) 2013-04-30
EA021805B1 EA021805B1 (ru) 2015-09-30

Family

ID=43778392

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201277A EA021805B1 (ru) 2010-03-11 2011-03-10 Кристаллические соли эффективного ингибитора вируса гепатита с

Country Status (17)

Country Link
US (3) US8530497B2 (ru)
EP (1) EP2545049B1 (ru)
JP (2) JP5687291B2 (ru)
KR (1) KR101756632B1 (ru)
CN (2) CN102844315B (ru)
AR (1) AR080494A1 (ru)
AU (1) AU2011224311B2 (ru)
BR (1) BR112012022812A2 (ru)
CA (1) CA2792684C (ru)
CL (1) CL2012002362A1 (ru)
EA (1) EA021805B1 (ru)
IL (1) IL221198A (ru)
MX (1) MX2012009964A (ru)
NZ (1) NZ601563A (ru)
TW (1) TW201200511A (ru)
UY (1) UY33270A (ru)
WO (1) WO2011112761A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2687526A1 (en) 2008-09-16 2014-01-22 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
NZ591030A (en) 2008-09-17 2012-10-26 Boehringer Ingelheim Int Combination of hcv ns3 protease inhibitor with interferon and ribavirin
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
BR112014005617A2 (pt) 2011-10-21 2017-06-13 Abbvie Inc tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
CA2902569A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Inhibitors of hepatitis c virus
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US10927067B2 (en) * 2016-11-28 2021-02-23 Sarin Parayil Organic crystalline salt of haloacetic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1033128T2 (sl) 1993-09-28 2012-02-29 Scherer Gmbh R P Izdelava mehke Ĺľelatinaste kapsule
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
BRPI0410456B8 (pt) * 2003-05-21 2021-05-25 Boehringer Ingelheim Int compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação
JP5156374B2 (ja) 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非環式ｈｃｖプロテアーゼインヒビターの調製方法
EP2687526A1 (en) 2008-09-16 2014-01-22 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor

Also Published As

Publication number Publication date
US20120059033A1 (en) 2012-03-08
EP2545049B1 (en) 2015-10-14
AR080494A1 (es) 2012-04-11
US20130317061A1 (en) 2013-11-28
KR101756632B1 (ko) 2017-07-11
AU2011224311B2 (en) 2014-08-14
EP2545049A1 (en) 2013-01-16
JP5687291B2 (ja) 2015-03-18
IL221198A (en) 2017-01-31
KR20130009966A (ko) 2013-01-24
JP2013522221A (ja) 2013-06-13
US20150166530A1 (en) 2015-06-18
US8530497B2 (en) 2013-09-10
CL2012002362A1 (es) 2013-01-11
CN104945396A (zh) 2015-09-30
JP2015143223A (ja) 2015-08-06
AU2011224311A1 (en) 2012-08-23
EA021805B1 (ru) 2015-09-30
UY33270A (es) 2011-10-31
CN102844315B (zh) 2015-05-20
US9382240B2 (en) 2016-07-05
TW201200511A (en) 2012-01-01
MX2012009964A (es) 2012-09-21
CN102844315A (zh) 2012-12-26
BR112012022812A2 (pt) 2018-05-15
NZ601563A (en) 2013-12-20
CA2792684C (en) 2018-07-31
WO2011112761A1 (en) 2011-09-15
IL221198A0 (en) 2012-10-31
CN104945396B (zh) 2018-02-27
CA2792684A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
EA201201277A1 (ru) Кристаллические соли эффективного ингибитора вируса гепатита с
BR112013001267A2 (pt) métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
EA201591220A1 (ru) Новые противовирусные агенты против инфекции вирусом гепатита в
EA201591244A1 (ru) Противовирусные соединения
EA201100482A1 (ru) Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
AR103222A1 (es) Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
EA201101587A1 (ru) 4-циано-3-бензоиламино-n-фенилбензамиды для использования в борьбе с вредителями
ECSP13013040A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
EA201390433A1 (ru) Ингибиторы вируса гепатита с
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
EA201200031A1 (ru) Инсектицидные соединения
CR20130531A (es) Derivados de nucleósidos 2'-sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales
EA201590384A1 (ru) 6-аминокислота-гетероарилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
EA201590868A1 (ru) Противовирусные соединения
EA201790417A3 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201390142A1 (ru) 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения
EA201390130A1 (ru) Способ получения противовирусных соединений
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201370078A1 (ru) Ингибиторы вируса гепатита с
EA201391685A1 (ru) Ингибиторы вируса гепатита с
EA201391265A1 (ru) Амиды индолкарбоновых и бензимидазолкарбоновых кислот в качестве инсектицидов и акарицидов
EA201300604A1 (ru) Соединения, предназначенные для лечения респираторно-синцитиальных вирусных инфекций
EA201391637A1 (ru) Ингибиторы вируса гепатита c
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU